&nbsp;

LungCancerScreening_ReferralForm.pdf

Apr 2021

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2020

Status: Current
ID: PET 2020-2

May 2021

Lettre de confidentialité de ContrôleCancerColorectal

Regimen

LURB

Cancer Type:

Lung,

Small Cell

Intent: Palliative

Drugs Used:

lurbinectedin (Unfunded)

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

LARO

Cancer Type:

Breast,

Central Nervous System,

Endocrine,

Adrenal,

Neuroendocrine,

Pancreatic Neuroendocrine,

Parathyroid,

Thymoma,

Thyroid,

Gastrointestinal,

Anus,

Colorectal,

Esophagus,

Gastric / Stomach,

Gastrointestinal Stromal Tumours,

Hepatobiliary / Liver / Bile Duct,

Mesothelioma (Peritoneal),

Neuroendocrine (GI),

Pancreas,

Rectal,

Small bowel and appendix,

Genitourinary,

Bladder / Urothelial,

Penile,

Prostate,

Renal cell / Kidney,

Testis,

Gynecologic,

Cervix,

Endometrial,

Germ Cell,

Gestational Trophoblastic Disease,

Ovary,

Uterine Sarcoma,

Vagina,

Vulva,

Head and Neck,

Larynx,

Nasopharynx,

Oral,

Paranasal Sinus,

Pharynx,

Salivary Gland,

Squamous Cell,

Kaposi's Sarcoma,

Lung,

Mesothelioma (Pleural),

Neuroendocrine (Lung),

Non-Small Cell,

Small Cell,

Sarcoma,

Desmoid Tumour,

Ewing's,

Ewing's and Soft Tissue,

GIST,

Giant Cell Tumour,

Kaposi's Sarcoma,

Osteogenic / Bone,

Soft Tissue,

Uterine,

Wilm's Tumour,

Skin,

Basal Cell,

Melanoma,

Merkel Cell,

Squamous Cell,

Unknown Primary

Intent: Palliative

Funding:

Exceptional Access Program

larotrectinib - For the treatment of unresectable locally advanced, or metastatic solid tumours with neurotrophic tyrosine receptor kinase (NTRK) gene fusion, according to clinical criteria

Drugs Used:

larotrectinib

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

ENFO

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Palliative

Funding:

New Drug Funding Program

Enfortumab Vedotin - Previously Treated Advanced or Metastatic Urothelial Cancer

Drugs Used:

enfortumab vedotin

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

ERDA

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Palliative

Drugs Used:

erdafitinib (Unfunded)

Quick Link(s):

Regimen Monograph

Nov 2021

Regimen

ENHE

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Trastuzumab Deruxtecan - Unresectable Locally Advanced or Metastatic Breast Cancer

New Drug Funding Program

Trastuzumab Deruxtecan - HER2-low Unresectable Locally Advanced or Metastatic Breast Cancer

Enhertu trastuzumab deruxtecan

Drugs Used:

Quick Link(s):

Regimen Monograph

May 2025

Document

LungCancerSxPathwayMap.pdf

Nov 2021

Document

EndometrialCancerDiagnosisPathwayMap.pdf

Dec 2021

Document